This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers (OneStep-1)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dipexium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01590758
First received: April 27, 2012
Last updated: May 19, 2017
Last verified: April 2017
Results First Received: April 14, 2017  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Triple (Participant, Care Provider, Investigator);   Primary Purpose: Treatment
Condition: Diabetic Foot Infection
Interventions: Drug: Topical pexiganan cream 0.8%
Drug: Topical placebo cream
Other: Standard wound care

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects recruited at outpatient clinics and practices

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No wash-out or run-in periods; eligible subjects were immediately assigned to treatment

Reporting Groups
  Description
Topical Pexiganan Cream 0.8%

Topical pexiganan cream 0.8%: 14 days of treatment + 14 days of follow-up (28-day trial period)

Standard wound care: 28-day trial period

Topical Placebo Control

Topical placebo cream: 14 days of treatment + 14 days of follow-up (28-day trial period)

Standard wound care: 28-day trial period


Participant Flow:   Overall Study
    Topical Pexiganan Cream 0.8%   Topical Placebo Control
STARTED   85   104 
COMPLETED   80   97 
NOT COMPLETED   5   7 
Withdrawal by Subject                0                3 
Physician Decision                1                2 
Lost to Follow-up                4                2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Topical Pexiganan Cream 0.8%

Topical pexiganan cream 0.8%: 14 days of treatment

Standard wound care: 28-day trial period

Topical Placebo Control

Topical placebo cream: 14 days of treatment

Standard wound care: 28-day trial period

Total Total of all reporting groups

Baseline Measures
   Topical Pexiganan Cream 0.8%   Topical Placebo Control   Total 
Overall Participants Analyzed 
[Units: Participants]
 85   104   189 
Age 
[Units: Years]
Mean (Standard Deviation)
     
Age   59.22  (10.14)   58.42  (10.97)   58.78  (10.58) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      22  25.9%      31  29.8%      53  28.0% 
Male      63  74.1%      73  70.2%      136  72.0% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
     
Hispanic or Latino      39  45.9%      52  50.0%      91  48.1% 
Not Hispanic or Latino      46  54.1%      52  50.0%      98  51.9% 
Unknown or Not Reported      0   0.0%      0   0.0%      0   0.0% 
Race (NIH/OMB) 
[Units: Participants]
Count of Participants
     
American Indian or Alaska Native      1   1.2%      0   0.0%      1   0.5% 
Asian      1   1.2%      1   1.0%      2   1.1% 
Native Hawaiian or Other Pacific Islander      0   0.0%      1   1.0%      1   0.5% 
Black or African American      19  22.4%      17  16.3%      36  19.0% 
White      64  75.3%      82  78.8%      146  77.2% 
More than one race      0   0.0%      0   0.0%      0   0.0% 
Unknown or Not Reported      0   0.0%      3   2.9%      3   1.6% 
Region of Enrollment 
[Units: Participants]
     
United States   85   104   189 
Wound surface area 
[Units: Participants]
Count of Participants
     
<1 sq cm      1   1.2%      1   1.0%      2   1.1% 
1 - <2 sq cm      41  48.2%      52  50.0%      93  49.2% 
>=2 sq cm      43  50.6%      51  49.0%      94  49.7% 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Clinical Response   [ Time Frame: 28 days ]

2.  Secondary:   Number of Participants With Microbiological Success   [ Time Frame: 28 days ]

3.  Secondary:   Number of Participants With Treatment-emergent Adverse Events (TEAE)   [ Time Frame: 28 days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Robert J DeLuccia
Organization: Dipexium Pharmaceuticals, Inc
phone: +19145226503
e-mail: delucciarj@gmail.com



Responsible Party: Dipexium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01590758     History of Changes
Other Study ID Numbers: DPX-305
Study First Received: April 27, 2012
Results First Received: April 14, 2017
Last Updated: May 19, 2017